Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353614 | 0.94 | CYP24A1 (0.46) | CYP24A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2356031 | 0.88 | CYP26A1 (0.43) | CYP24A1MAPTHPGDHTTCYP3A4 | |
| SCHEMBL2348989 | 0.83 | ALDH1A1 (0.41) | CYP24A1MAPTHPGDHTTCYP3A4 | |
| SCHEMBL2352825 | 0.81 | CYP26A1 (0.43) | CYP24A1MAPTHPGDPOLBHTT | |
| SCHEMBL11704299 | 0.81 | CYP19A1 (0.48) | CYP24A1SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL4642685 | 0.79 | FPR2 (0.47) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL2352269 | 0.77 | CYP19A1 (0.43) | LRRK2CYP3A4CYP17A1 | |
| SCHEMBL2351912 | 0.76 | ALDH1A1 (0.41) | CYP24A1MAPTHPGDHTTCYP3A4 | |
| SCHEMBL9788661 | 0.76 | CYP17A1 (0.63) | CYP24A1KDM4ECYP17A1 | |
| SCHEMBL6437508 | 0.74 | FPR2 (0.47) | MAPTSMN1; SMN2MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0337929-A1 | N-substituted imidazoles, process for their preparation and their pharmaceutical application | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-10-18 | — | — | EP | claimed |
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | UNIVERSITY OF MASSACHUSETTS (US) | 2026-03-31 | — | — | US | disclosed |
| US-20210109085-A1 | METHODS FOR PREDICTING ER-MEDIATED DNA DAMAGE | UNIVERSITY OF MASSACHUSETTS | 2021-04-15 | — | — | US | disclosed |
| US-8871750-B2 | Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus | WAYNE STATE UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8008333-B2 | Inducing ovulation; increasing response to follicle stimulating hormone | ARES TRADING S.A. (CH) | 2011-08-30 | — | — | US | disclosed |
| US-7846957-B2 | Aromatase inhibition to enhance assisted reproduction | ARES TRADING S.A. (CH) | 2010-12-07 | — | — | US | disclosed |
| US-7820706-B2 | Multiple dose aromatase inhibitor for treating infertility | ARES TRADING S.A. (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CASPER ROBERT F | 2010-04-29 | — | — | US | disclosed |
| EP-1898923-A4 | AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION | CASPER ROBERT F (CA) | 2009-05-20 | — | — | EP | disclosed |
| EP-1898923-A1 | AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION | Casper, Robert F. (CA) | 2008-03-19 | — | — | EP | disclosed |
| EP-1534265-A1 | COMBINATION OF AN AROMATASE INHIBITOR WITH A BISPHOSPHONATE | Novartis AG (CH) | 2005-06-01 | — | — | EP | disclosed |
| US-20040235804-A1 | Inducing ovulation in a female suffering from anovulatory infertility by administering two or more daily doses of at least one aromatase inhibitor | ARES TRADING S.A. (CH) | 2004-11-25 | — | — | US | disclosed |
| US-20040235812-A1 | Pharmaceutical composition comprisng an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male | CASPERS ROBERT F (CA) | 2004-11-25 | — | — | US | disclosed |
| US-20040204393-A1 | use of aromatase inhibitor in production of medicament for improving implantation and pregnancy rates for female undergoing assisted reproduction treatment comprising daily doses of aromatase inhibitor for administration during assisted reproduction or ovarian stimulation cycles to reduce serum estradiol | ARES TRADING S.A. (CH) | 2004-10-14 | — | — | US | disclosed |
| US-20040171660-A1 | Single dose aromatase inhibitor for treating infertility | ARES TRADINS S.A. (CH) | 2004-09-02 | — | — | US | disclosed |
| WO-2002083240-A9 | AROMATASE INHIBITION TO ENHANCE ASSISTED REPRODUCTION | ARES TRADING SA (CH) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004012728-A1 | COMBINATION OF AN AROMATASE INHIBITOR WITH A BISPHOSPHONATE | NOVARTIS AG (CH) | 2004-02-12 | — | — | WO | disclosed |
| US-5583128-A | ADMINISTERING A SIDE EFFECT REDUCED AROMATASE INHIBITOR | CIBA-GEIGY CORPORATION (US) | 1996-12-10 | — | — | US | disclosed |
| US-4916144-A | ESTROGEN-CAUSE DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-04-10 | — | — | US | disclosed |
| EP-0337929-A1 | N-substituted imidazoles, process for their preparation and their pharmaceutical application | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235812-A1 | Pharmaceutical composition comprisng an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male | CYP19A1, SHBG, CYP17A1 | CYP24A1 98/4885MAPT 1752/4885SMN1; SMN2 2023/4885 |
| US-20040235804-A1 | Inducing ovulation in a female suffering from anovulatory infertility by administering two or more daily doses of at least one aromatase inhibitor | CYP19A1, FSHR, GNRHR | CYP24A1 239/4885MAPT 4870/4885SMN1; SMN2 4690/4885 |
| US-20040204393-A1 | use of aromatase inhibitor in production of medicament for improving implantation and pregnancy rates for female undergoing assisted reproduction treatment comprising daily doses of aromatase inhibitor for administration during assisted reproduction or ovarian stimulation cycles to reduce serum estradiol | CYP19A1, CYP11A1, HSD17B11 | CYP24A1 416/4885MAPT 4794/4885SMN1; SMN2 4680/4885 |
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CYP19A1, SHBG, HSD17B11 | CYP24A1 90/4885MAPT 4649/4885SMN1; SMN2 2780/4885 |
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | ESR1, ESR2, ESRRA | CYP24A1 269/4885MAPT 1900/4885SMN1; SMN2 2390/4885 |
| US-20040171660-A1 | Single dose aromatase inhibitor for treating infertility | CYP19A1, FSHR, SHBG | CYP24A1 718/4885MAPT 4849/4885SMN1; SMN2 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.